Lenvatinib
|
- ₹0
- Product name: Lenvatinib
- CAS: 417716-92-8
- MF: C21H19ClN4O4
- MW: 426.85
- EINECS:1592732-453-0
- MDL Number:MFCD16038644
- Synonyms:4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide;E7080 (Lenvatinib);ER-203492-00;1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea;4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide XEN445;E70801-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea;4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate;LENVATINIB
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :>216°C (dec.)
Boiling point :627.2±55.0 °C(Predicted)
Density :1.46
storage temp. :-20°C
solubility :Soluble in DMSO (up to 20 mg/ml)
form :solid
pka :13.09±0.70(Predicted)
color :White
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
CAS DataBase Reference :417716-92-8
Boiling point :627.2±55.0 °C(Predicted)
Density :1.46
storage temp. :-20°C
solubility :Soluble in DMSO (up to 20 mg/ml)
form :solid
pka :13.09±0.70(Predicted)
color :White
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
CAS DataBase Reference :417716-92-8
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|
Description
Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.More related product prices
PF-06463922 Nintedanib Axitinib MK-1775 Everolimus 4-chloro-7-Methoxyquinoline-6-carboxaMide 4-Amino-3-chlorophenol Methyl 4-chloro-7-Methoxyquinoline-6-carboxylate Methyl 7-Methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylate lenvatinib Mesylate 52671-64-4 Dacomitinib (PF299804) 871700-17-3 OTAVA-BB 1115529 Cabozantinib GZD 824 Doxorubicin hydrochloride PonatinibRelated product price
- Axitinib
₹12849.28 - Everolimus
₹11709-51483.7 - lenvatinib Mesylate
₹9093
